Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Zhang, Jianli ^a   Jiang, Xiuli ^a   Zhang, Jian ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Pancreatic ductal adenocarcinoma; Prognosis; XB130

Indexed keywords

ADAPTOR PROTEIN; FLUOROURACIL; GEMCITABINE; TEGAFUR; UNCLASSIFIED DRUG; XB130 PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; RISK FACTOR; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CYTOPLASM; RETROSPECTIVE STUDY; TISSUE SECTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899146780     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-49     Document Type: Article

References (19)

1. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993, 165:68-72. 10.1016/S0002-9610(05)80406-4, 8380315.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244:10-15. 10.1097/01.sla.0000217673.04165.ea, 1570590, 16794383.
3. Kleeff J, Michalski C, Friess H, Buchler MW. Pancreatic ductal adenocarcinoma: from bench to 5-year survival. Pancreas 2006, 33:111-118. 10.1097/01.mpa.0000229010.62538.f2, 16868475.
4. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic ductal adenocarcinoma stem cells. Cancer Res 2007, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
5. Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K. Prognostic factors after resection of pancreatic ductal adenocarcinoma. World J Surg 2009, 33:104-110. 10.1007/s00268-008-9807-2, 19011933.
6. Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013, 54:643-649. 10.3349/ymj.2013.54.3.643, 3635646, 23549809.
7. Hilgers W, Kern SE. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999, 26:1-12. 10.1002/(SICI)1098-2264(199909)26:1<1::AID-GCC1>3.0.CO;2-X, 10440999.
8. Shiozaki A, Liu M. Roles of XB130, a novel adaptor protein, in cancer. J Clin Bioinforma 2011, 1:10. 10.1186/2043-9113-1-10, 3164603, 21884627.
9. Xu J, Bai XH, Lodyga M, Han B, Xiao H. XB130, a novel adaptor protein for signal transduction. J Biol Chem 2007, 282:16401-16412. 10.1074/jbc.M701684200, 17412687.
10. Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T. XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol 2011, 178:391-401. 10.1016/j.ajpath.2010.11.024, 3070596, 21224076.
11. Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, Kitagawa M, Nakou Y, Kishimoto M, Liu M, Otsuji E. XB130 as an independent prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 2013, 20:3140-3150. 10.1245/s10434-012-2474-4, 22805860.
12. Zuo Q, Huang H, Shi M, Zhang F, Sun J, Bin J, Liao Y, Liao W. Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec (Hoboken) 2012, 295:423-431. 10.1002/ar.21531, 22190283.
13. Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, Wang N, Wu Y, Liao Y, Liao W. Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One 2012, 7:e41660. 10.1371/journal.pone.0041660, 3426513, 22927913.
14. Sobin LH, Gospodarowicz MK, Ch W. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours 2009, Oxford, UK: Wiley-Blackwell, 7.
15. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours 2002, 93-96. New York: John Wiley & Sons, 6.
16. Mukaiya M, Hirata K, Satoh T. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg 1998, 22:248-252. 10.1007/s002689900378, 9494416.
17. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Surg 2002, 9:1-11. 10.1007/s005340200000, 12021893.
18. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic ductal adenocarcinoma. Br J Surg 2011, 98:1041-1055. 10.1002/bjs.7574, 21644238.
19. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnel MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic Experience (1975-2005). J Clin Oncol 2008, 26:3511-3516. 10.1200/JCO.2007.15.8782, 18640932.